文献速递淋巴瘤

省略放疗与高危早期霍奇金淋巴瘤疾病控制较差相关

Omission of Radiation Therapy is Associated with Inferior Disease Control in High Risk Early-Stage Hodgkin Lymphoma.
PubMed 文献 · Blood Adv · 2026-10-28

该多中心回顾性研究分析810例I/II期经典霍奇金淋巴瘤成人患者,倾向性匹配后比较化疗联合放疗(CMT)与单纯化疗。匹配后5年OS无差异,5年PFS边缘显著 favoring CMT;在 bulky 病变和 iPET 阳性(DS≥4)亚组中 CMT 显著改善 PFS。iPET 反应是最强独立预测因素,支持风险适应治疗。

要点

  • 匹配后5年OS CMT 98.6% vs 单纯化疗97.3%(p=0.620),无显著差异。
  • 匹配后5年PFS CMT 87.2% vs 单纯化疗81.4%(p=0.053),边缘显著。
  • bulky病变和iPET阳性(DS≥4)患者从CMT中显著获益。

核心结论

  • 在高危早期霍奇金淋巴瘤中,省略放疗与较差的疾病控制相关,尤其在bulky病变和iPET阳性患者中。
  • iPET反应是进展和死亡的最强独立预测因素。

研究设计与样本

  • 多中心回顾性分析,纳入2012年1月至2022年1月八家学术中心的810例I/II期霍奇金淋巴瘤成人患者。
  • 采用倾向性匹配比较CMT与单纯化疗,匹配后样本480例;并进行亚组分析。

主要发现

  • 匹配后5年OS:CMT 98.6% vs 单纯化疗97.3%(p=0.620)。
  • 匹配后5年PFS:CMT 87.2% vs 单纯化疗81.4%(p=0.053)。
  • bulky病变患者5年PFS:CMT 91.8% vs 单纯化疗73.0%(HR 3.77;p=0.005)。
  • iPET阳性(DS≥4)患者5年PFS:CMT 74.9% vs 单纯化疗51.9%(HR 2.97;p=0.020)。
  • iPET反应对进展的HR 7.02、对死亡的HR 6.97;PFS随DS分组下降(DS1-2: 92.2%;DS3: 79.4%;DS4-5: 46.4%)。

关键数值与推荐

  • iPET阳性患者中,接受非计划巩固放疗者需挽救治疗的比例低于单纯化疗升级者(29.0% vs 45.2%;p=0.037)。
  • CMT晚期毒性更常见,但69%的第二恶性肿瘤发生在放疗野外。

临床怎么用

  • 支持基于风险适应和生物标志物驱动的治疗选择,高危早期患者应考虑包含放疗的CMT。
  • iPET反应可指导治疗决策,DS≥4患者可能从巩固放疗中获益。

局限性

  • 回顾性设计,可能存在选择偏倚。
  • 需前瞻性试验验证现代放疗技术和iPET适应算法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Early-stage classical Hodgkin lymphoma (HL) is highly curable, yet optimal frontline treatment remains contested. Combined modality therapy (CMT) with chemotherapy followed by radiotherapy (RT) has been the standard, but concern over RT-associated toxicities has driven adoption of chemotherapy-alone approaches despite randomized trials failing to demonstrate noninferiority with RT omission. We analyzed 810 adult patients treated across eight academic centers for stage I/II HL between 1/2012 and 1/2022, comparing outcomes with CMT and chemotherapy alone. Primary endpoints were progression-free (PFS) and overall survival (OS); propensity-score matching was conducted to homogenize baseline characteristics between the groups, and subgroup analyses were conducted to identify clinical features associated with differential benefit. Among 480 propensity-matched patients, five-year OS was 98.6% with CMT versus 97.3% with chemotherapy alone (p=0.620); five-year PFS was 87.2% vs 81.4% (p=0.053). CMT conferred significantly superior PFS in patients with bulky disease (91.8% vs 73.0%; HR 3.77; p=0.005) and interim (iPET)-positive disease (Deauville score (DS)≥4; 74.9% vs 51.9%; HR 2.97; p=0.020). iPET response was the strongest independent predictor of both progression (HR 7.02) and mortality (HR 6.97), with PFS declining markedly across DS groups (DS1-2: 92.2%; DS3: 79.4%; DS4-5: 46.4%). Among iPET-positive patients, those receiving unplanned consolidative RT required less salvage therapy than those managed with chemotherapy escalation alone (29.0% vs. 45.2%; p=0.037). Late toxicities were more frequent with CMT, though 69% of second malignancies occurred outside the RT field. These findings support risk-adapted, biomarker-driven treatment selection and the need for prospective trials incorporating modern RT techniques and iPET-adapted algorithms.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Dave, Dreyfuss, Moskowitz, et al. Omission of Radiation Therapy is Associated with Inferior Disease Control in High Risk Early-Stage Hodgkin Lymphoma. Blood Adv. 2026. PMID: 42950253. doi:10.1182/bloodadvances.2026021839

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。